Skip to content

Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02175459
Enrollment
100
Registered
2014-06-26
Start date
2010-08-31
Completion date
2024-12-31
Last updated
2024-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DIABETES, Endocrine Pancreas Disorder, Exocrine Pancreas Conditions, Exocrine Pancreatic Dysfunction, Exocrine Pancreatic Insufficiency, GLUCOSE METABOLISM, PANCREATIC ISLETS

Keywords

Beta cell function, Islet cell crosstalk, Incretin intraislet System, Biomarkers, MiRNA, ncRNA, Pancreatic exocrine endocrine crosstalk, Diabetes of exocrine pancreas

Brief summary

Regeneration of mature cells that produce functional insulin represents a major focus of current diabetes research aimed at restoring beta cell mass in patients with most forms of diabetes. The capacity to adapt in response to diverse physiological conditions during life and the consequent ability to cope for increased metabolic demands is a distinctive feature of the endocrine pancreas in the regulation of glucose homeostasis. Both beta and alpha cells are dynamically regulated to continually maintain a balance between proliferation, neogenesis, and apoptosis. In this proposal, the investigators will focus on exploring key mechanism(s) that potentially regulate islet cell plasticity in altered glucose metabolic states. Investigators will explore in a unique cohort of individuals who undergo duodenal pancretectomy. Prior to their surgery will be performed in vivo studies (Hyperglycemic clamp, Euglycemic Hyperinsulinemic clamp and Mixed Meal Tests) to accurately assess glucose homeostasis parameters to classify each individual into metabolic phenotypes. Then exploit the opportunity to collect pancreas samples from these patients who will be evaluated again after surgery, the investigators will determine the ability of the remnant pancreas to compensate for the acute reduction in islet mass and perform correlations between ex vivo and in vivo parameters. Specifically, the patients will be subjected to incretin secretion (mixed meal), metabolic status (OGTT), insulin secretion characteristics (first and second phase responses), β-cell insulin content evaluation (arginine bolus). Subsequently, pancreas samples will be evaluated for morphometry, and proteomics and gene expression analyses of islet cell samples obtain by laser capture will allow a detailed investigation of mechanisms that contribute to islet plasticity. The overall goal of this project is to investigate key mechanisms driving the ability of islet mass to adapt to diverse metabolic states. We aim to explore modifications in gene expression and proteomics and correlate them with specific metabolic phenotypes, in order to determine key regulators of islet morphology.

Interventions

None listed

Sponsors

Joslin Diabetes Center
CollaboratorOTHER
University of Siena
CollaboratorOTHER
University of Copenhagen
CollaboratorOTHER
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche
CollaboratorNETWORK
University of Pisa
CollaboratorOTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

* SCHEDULED FOR PANCREATECTOMY * NO DIABETIC and DIABETIC

Exclusion criteria

* CHRONIC DESEASES * STEROID THERAPY

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in metabolic status (normal glucose tolerance, impaired glucose tolerance, diabetes)baseline, 1 month after surgery and 1year after surgeryMetabolic status will be determined with oral glucose tolerance test and patients will be classified according their metabolic status (after 1 month and 1 year after surgery).

Secondary

MeasureTime frameDescription
Change in insulin secretion from baselinebaseline, 1 month after surgery and 1 year after surgeryInsulin secretion will be measured by Hyperglicemic clamp.
islet cell areas (beta, Alpha and delta cell positive area)baselinePancreas section will be immunostained for insulin, glucagon and somatostatin and Each section will be analyzed separately by measuring total insulin, glucagon or somatostatin positive areas, as well as the total pancreas section area, using Image Pro Plus software version 4. 5.1 . The β, α or δ cell areas will be expressed as percentage of total pancreas section area.
Changes in incretin levels from baselinebaseline, 1 months after surgery and 1 year after surgeryIncretin levels (GLP1 and GIP) will be measured during mixed meal test.
changes in intraislet ncRNA in different metabolic statusbaselinencRNA sequenting in plasma and pancreas samples
changes in beta cell function in the context of disease of exocrine pancreasbaselineInsulin secretion will be measured by Hyperglicemic clamp and ogtt.

Other

MeasureTime frameDescription
change in gene expression analysis among different groups of baseline metabolic statusbaselineExtract of islet cells will be dissected from pancreatic sections by laser capture microdissection and then extracted RNA will be analyzed by real time PCR analysis.

Countries

Italy

Contacts

Primary ContactTERESA MEZZA, MD, PHD
TERESA.MEZZA@UNICATT.IT+39063015

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026